- Home
- SRZN vs CALC Comparison
SRZN vs CALC Comparison
Compare SRZN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- CALC
- Stock Information
- Founded
- SRZN 2015
- CALC 2011
- Country
- SRZN United States
- CALC United States
- Employees
- SRZN N/A
- CALC N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- CALC Health Care
- Exchange
- SRZN Nasdaq
- CALC Nasdaq
- Market Cap
- SRZN 37.7M
- CALC 36.0M
- IPO Year
- SRZN N/A
- CALC N/A
- Fundamental
- Price
- SRZN $11.43
- CALC $1.84
- Analyst Decision
- SRZN Strong Buy
- CALC Strong Buy
- Analyst Count
- SRZN 2
- CALC 3
- Target Price
- SRZN $38.50
- CALC $16.33
- AVG Volume (30 Days)
- SRZN 12.4K
- CALC 75.0K
- Earning Date
- SRZN 03-31-2025
- CALC 05-12-2025
- Dividend Yield
- SRZN N/A
- CALC N/A
- EPS Growth
- SRZN N/A
- CALC N/A
- EPS
- SRZN N/A
- CALC N/A
- Revenue
- SRZN $10,655,000.00
- CALC N/A
- Revenue This Year
- SRZN N/A
- CALC N/A
- Revenue Next Year
- SRZN N/A
- CALC N/A
- P/E Ratio
- SRZN N/A
- CALC N/A
- Revenue Growth
- SRZN N/A
- CALC N/A
- 52 Week Low
- SRZN $6.00
- CALC $1.81
- 52 Week High
- SRZN $18.17
- CALC $6.27
- Technical
- Relative Strength Index (RSI)
- SRZN 53.51
- CALC 42.94
- Support Level
- SRZN $10.34
- CALC $1.81
- Resistance Level
- SRZN $14.00
- CALC $2.21
- Average True Range (ATR)
- SRZN 0.95
- CALC 0.15
- MACD
- SRZN 0.00
- CALC 0.01
- Stochastic Oscillator
- SRZN 47.36
- CALC 47.10
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.